Oxadiazoles and thiadiazoles: Novel α-glucosidase inhibitors

Oxadiazoles and thiadiazoles 1-37 were synthesized and evaluated for the first time for their alpha-glucosidase inhibitory activities. As a result, fifteen of them 1, 4, 5, 7, 8, 13, 17, 23, 25, 30, 32, 33, 35, 36 and 37 were identified as potent inhibitors of the enzyme. Kinetic studies of the most active compounds (oxadiazoles 1, 23 and 25, and thiadiazoles 35 and 37) were carried out to determine their mode of inhibition and dissociation constants K-i. The most potent compound of the oxadiazole series (compound 23) was found to be a non-competitive inhibitor (K-i = 4.36 +/- 0.017 mu M), while most potent thiadiazole 35 was identified as a competitive inhibitor (K-i = 6.0 +/- 0.059 mu M). The selectivity and toxicity of these compounds were also studied by evaluating their potential against other enzymes, such as carbonic anhydrase-II and phosphodiesterase-I. Cytotoxicity was evaluated against rat fibroblast 3T3 cell line. Interestingly, these compounds were found to be inactive against other enzymes, exhibiting their selectivity towards alpha-glucosidase. Inhibition of alpha-glucosidase is an effective strategy for controlling post-prandial hyperglycemia in diabetic patients. alpha-Glucosidase inhibitors can also be used as anti-obesity and anti-viral drugs. Our study identifies two novel series of potent a-glucosidase inhibitors for further investigation. (C) 2014 Elsevier Ltd. All rights reserved.